PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20531297-0	2010	Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.	Tamoxifen	77-86	ret proto-oncogene	Homo sapiens	39-42	
20531297-5	2010	In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug.	Tamoxifen	3-12	ret proto-oncogene	Homo sapiens	35-38	
20531297-5	2010	In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug.	Tamoxifen	145-154	ret proto-oncogene	Homo sapiens	35-38	
20531297-6	2010	In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity.	Tamoxifen	3-12	ret proto-oncogene	Homo sapiens	56-59	
20531297-6	2010	In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity.	Tamoxifen	69-78	ret proto-oncogene	Homo sapiens	56-59	
20531297-7	2010	Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ERalpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of RET-positive tumors.	Tamoxifen	292-301	ret proto-oncogene	Homo sapiens	119-122	
20531297-7	2010	Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ERalpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of RET-positive tumors.	Tamoxifen	292-301	ret proto-oncogene	Homo sapiens	359-362	
20531297-8	2010	Together these findings identify RET as a potentially important therapeutic target in ERalpha-positive breast cancers and in particular in tamoxifen-resistant tumors.	Tamoxifen	139-148	ret proto-oncogene	Homo sapiens	33-36